Cationic lipid-conjugated dexamethasone as a selective antitumor agent
- PMID: 24992071
- DOI: 10.1016/j.ejmech.2014.06.051
Cationic lipid-conjugated dexamethasone as a selective antitumor agent
Abstract
Dexamethasone (Dex) is one of the highly potent synthetic glucocorticoids. It exhibits prominent anti-inflammatory but moderate anti-proliferative activities. It is widely used along side chemotherapy to alleviate toxic side effects. Additionally, Dex is also a potent inducer of gluconeogenesis. However, its overuse critically desensitizes cells against chemotherapy. Herein, we report on the development of a new class of cationic lipid-Dex conjugates in which the C-8 carbon chain analogue (DX8) exhibited glucocorticoid receptor (GR)-mediated, caspase-3-assisted, cancer cell-selective anti-proliferative activity. Melanoma tumors in DX8-treated mice exhibited significantly reduced tumor aggressiveness with respect to tumors in Dex-treated mice. Tumor lysates prepared from DX8-treated group showed elevated levels of p53. DX8-treated cancer cells showed clear degradation of kinase JAK3/STAT3 protein levels. Additionally, DX8-treatment decreased the level of VEGFR2 in tumor-endothelial cells implying DX8's anti-proliferative roles in both tumor cells and tumor neovascular cells. Collectively, our results demonstrate potent anti-angiogenic, and selective JAK3/STAT3 down-regulating anticancer characteristics of DX8, a new dexamethasone-based antitumor molecule.
Keywords: Apoptosis; Cationic lipid; Dexamethasone; Glucocorticoid receptor; Tumor.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Structure-activity study to develop cationic lipid-conjugated haloperidol derivatives as a new class of anticancer therapeutics.J Med Chem. 2011 Apr 14;54(7):2378-90. doi: 10.1021/jm101530j. Epub 2011 Mar 10. J Med Chem. 2011. PMID: 21391684
-
Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.Int J Mol Med. 2008 Oct;22(4):489-96. Int J Mol Med. 2008. PMID: 18813856
-
Epicatechin gallate induces cell death via p53 activation and stimulation of p38 and JNK in human colon cancer SW480 cells.Nutr Cancer. 2013;65(5):718-28. doi: 10.1080/01635581.2013.795981. Nutr Cancer. 2013. PMID: 23859040
-
Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.J Chemother. 2013 Oct;25(5):298-308. doi: 10.1179/1973947813Y.0000000079. J Chemother. 2013. PMID: 24070138
-
β-Ionone and its analogs as promising anticancer agents.Eur J Med Chem. 2016 Nov 10;123:141-154. doi: 10.1016/j.ejmech.2016.07.037. Epub 2016 Jul 20. Eur J Med Chem. 2016. PMID: 27474930 Review.
Cited by
-
Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.Transl Breast Cancer Res. 2023 Apr 30;4:16. doi: 10.21037/tbcr-23-17. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751461 Free PMC article. Review.
-
Dexamethasone Conjugates: Synthetic Approaches and Medical Prospects.Biomedicines. 2021 Mar 27;9(4):341. doi: 10.3390/biomedicines9040341. Biomedicines. 2021. PMID: 33801776 Free PMC article. Review.
-
The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors.J Cell Signal. 2020;1(3):42-49. J Cell Signal. 2020. PMID: 32728672 Free PMC article.
-
Dexamethasone Inhibits Spheroid Formation of Thyroid Cancer Cells Exposed to Simulated Microgravity.Cells. 2020 Feb 5;9(2):367. doi: 10.3390/cells9020367. Cells. 2020. PMID: 32033410 Free PMC article.
-
PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer.Cancers (Basel). 2019 Feb 16;11(2):232. doi: 10.3390/cancers11020232. Cancers (Basel). 2019. PMID: 30781490 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
